BPC-157, a synthetic pentadecapeptide derived from a sequence in human gastric juice, is one of the most frequently studied experimental peptides in musculoskeletal wound-healing models. This review examines what the preclinical literature actually shows across tendon, ligament, muscle, and bone, and where the evidence stops.

The research question

Soft-tissue and musculoskeletal injuries are a large share of the burden treated in sports medicine, which is part of why peptides with reported regenerative signals attract research attention.¹ Tendons, ligaments, and the myotendinous junction are notoriously slow to heal because they are poorly vascularised and relatively hypocellular, and investigators have long searched for interventions that modulate the local repair environment.³

BPC-157 (body protection compound-157) is a stable gastric pentadecapeptide, a 15–amino-acid fragment isolated from a protein in human gastric juice. It first entered the literature as an anti-ulcer and cytoprotective agent, and the same laboratories subsequently reported healing effects in extra-gastrointestinal tissues, including tendon, ligament, muscle, and bone.¹¹ The research question addressed here is narrow and deliberately framed: what does the experimental record demonstrate about BPC-157 in musculoskeletal repair models, and how far can those observations legitimately be extrapolated? The short answer is that the preclinical signal is consistent and reproducible within its models, while human validation is effectively absent.

How broad is the preclinical evidence?

Across four tissue classes, the preclinical picture is unusually internally consistent. A 2025 systematic review that screened 544 records and included 36 studies (35 preclinical, 1 clinical) concluded that in animal models BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries.¹ A dedicated review of musculoskeletal soft-tissue healing reached a similar summary while stressing that most work comes from a small number of groups and small rodent samples, and that efficacy is unconfirmed in humans.³

Tendon

In a transected rat Achilles model and in explant culture, BPC-157 accelerated the outgrowth of tendon fibroblasts, improved cell survival under oxidative (H₂O₂) stress, and dose-dependently increased fibroblast migration and spreading in vitro.⁴ These are cellular readouts relevant to defect closure rather than clinical endpoints, but they are mechanistically coherent with the tissue-level repair reported elsewhere.

Ligament

In a rat medial collateral ligament transection followed for 90 days, intraperitoneal, per-oral, and topical BPC-157 — each given without a carrier — produced consistent functional, biomechanical, macroscopic, and histological improvements relative to controls.⁸ The effective doses spanned an extremely wide range (micrograms to nanograms per kilogram), a recurring and somewhat unusual feature of this literature.

Skeletal muscle and the myotendinous junction

Muscle-injury models describe accelerated functional recovery and modulated angiogenesis after crush or transection injury.⁷ In a rat model of quadriceps myotendinous-junction detachment — a defect that does not close spontaneously — BPC-157 was associated with improved macroscopic, microscopic, biomechanical, and functional outcomes, reduced muscle atrophy, and normalised nitric-oxide and oxidative-stress levels at the junction.¹⁰

Bone

In a rabbit segmental bone-defect model that failed to heal in all untreated controls over six weeks, local or intramuscular BPC-157 improved callus formation and histomorphometric healing to a degree the authors compared with autologous bone-marrow or cortical-graft implantation.⁹ This is among the older studies and, like the others, remains unreplicated in humans.

Two caveats travel with this table. First, effects are frequently reported to persist after dosing stops, and second, the dose–response behaviour is atypical — nanogram and microgram regimens sometimes yield comparable results. Both features are noted in the primary reports and neither has been mechanistically resolved.⁸⁹

Molecular pathways under investigation

The proposed mechanisms cluster around three overlapping themes: angiogenesis, cytoskeletal reorganisation with fibroblast migration, and sensitisation of connective tissue to anabolic signalling. A 2025 narrative review summarised these as activation of VEGFR2 and nitric-oxide synthesis via the Akt–eNOS axis, engagement of ERK1/2 signaling, and anti-inflammatory and neuromuscular-stabilising effects, particularly in poorly vascularised tissue such as tendon and the myotendinous junction.²

• VEGFR2–Akt–eNOS signaling. This axis is the most consistently reported and underlies the angiogenic/angiomodulatory phenotype described across muscle, tendon, and bone models.⁶
• FAK–paxillin activation. In tendon fibroblasts, BPC-157 dose-dependently increased phosphorylation of focal adhesion kinase and paxillin without changing total protein, promoting F-actin formation, migration, and spreading — a plausible route to organised matrix remodelling.⁴
• Growth hormone receptor up-regulation. cDNA microarray analysis identified the growth hormone receptor as one of the most strongly up-regulated genes in BPC-157-treated tendon fibroblasts; adding growth hormone then increased proliferation via JAK2 signaling. This modulates responsiveness to endogenous anabolic signals rather than acting as a growth-hormone analogue itself.⁵

It is worth emphasising that these pathways are described predominantly in rodent tissue and cultured cells. They form a coherent mechanistic narrative, but a coherent narrative is not the same as demonstrated causation in intact human tissue, and several of the reported nodes have been characterised by only one or two research groups.³

Angiogenesis as the central theme

If a single thread runs through the BPC-157 musculoskeletal literature, it is vascular. Early immunohistochemical work in crushed and transected muscle and tendon reported that BPC-157 up-regulated VEGF expression and modulated — rather than simply maximised — angiogenesis, with no direct angiogenic effect observed on cell cultures alone.⁷ That distinction matters: the peptide appears to act on the injured-tissue context, not as a generic mitogen.

A mechanistic study using chick chorioallantoic membrane assays, endothelial tube-formation assays, and a rat hind-limb ischaemia model tied these observations to VEGFR2. BPC-157 increased vessel density in vivo and in vitro, accelerated blood-flow recovery in ischaemic muscle, and up-regulated and internalised VEGFR2 while activating the VEGFR2–Akt–eNOS cascade; blocking endocytosis with dynasore suppressed both VEGFR2 internalisation and tube formation.⁶ Because tendons and ligaments heal slowly in part due to limited perfusion, a vascular mechanism is a biologically reasonable explanation for the repair signals seen in those tissues — which is precisely why researchers pair vascular endpoints with structural ones when designing new experiments.

What human and translational data exist?

Very little. The 2025 systematic review identified a single clinical study among its included records: a retrospective report in which 7 of 12 patients with unspecified chronic knee pain described relief lasting more than six months after intra-articular BPC-157 injection.¹ That study had no randomisation, no blinding, no control arm, and no imaging to confirm tissue-level change, so it carries minimal evidentiary weight. A separate 2025 scoping review found only three pilot human studies in total — covering intra-articular knee pain, interstitial cystitis, and an intravenous safety/pharmacokinetics evaluation — and concluded that BPC-157 should be considered investigational until well-designed trials are conducted.²

A 2026 orthopaedic primer on injectable peptides reached the same conclusion from the clinician's side: BPC-157 showed potential in tendon and muscle repair, but the findings are largely unvalidated in humans, the single human case series has significant methodological flaws, and indications, dosing, frequency, and treatment duration remain unknown.¹² Reported pharmacokinetics are also relevant to translational planning: the systematic review notes hepatic metabolism, a half-life under 30 minutes, and renal clearance, alongside an absence of human safety data.¹

Regulatory status and research constraints

As of 2026, BPC-157 is not approved by the U.S. Food and Drug Administration for any indication, and it is prohibited in professional and Olympic-level sport.¹ These facts define the boundary of legitimate work: the compound is a research material, and studies belong in controlled preclinical and laboratory settings under the appropriate oversight.

Regulatory oversight

Investigations involving BPC-157 must comply with local and international rules governing experimental compounds. Animal studies require institutional review-board and ethics-committee approval and adherence to responsible-conduct and reporting standards.

Animal-welfare considerations

Because the evidence base rests heavily on rodent and rabbit models, adherence to humane endpoints, the 3Rs (replacement, reduction, refinement), and minimisation of suffering is central to both the ethical and the scientific validity of this work.

Data integrity and reproducibility

The concentration of this literature in a limited number of laboratories makes independent replication and transparent reporting especially important. Detailed records, standardised protocols, and peer-reviewed dissemination are what will move the field beyond its current investigational status.

Interpreting the evidence honestly

The most defensible reading of the record is this: BPC-157 produces reproducible, mechanistically coherent repair signals across multiple musculoskeletal tissues in animals, driven substantially by an angiogenic VEGFR2–Akt–eNOS mechanism and supported by fibroblast-migration and growth-hormone-receptor findings. At the same time, essentially none of this has been confirmed in adequately controlled human studies, safety in humans is uncharacterised, and the compound holds no regulatory approval.¹² For researchers, that combination defines an open, well-motivated question rather than a settled one — and it underscores why input-material consistency matters when designing reproducible experiments with peptides such as BPC-157 or related tools like TB-500.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.